慢性肾衰病人可溶性细胞间粘附分子-1和血管细胞粘附分子-1的检测

目的　探讨慢性肾衰病人 (CRF)外周血中可溶性细胞间粘附分子 1(SICAM 1)、血管细胞粘附分子 1(SVCAM 1)的临床价值。方法　以酶联免疫吸附测定法 (ELISA)检测正常人和慢性肾衰病人 (CRF)外周血中SICAM 1、SVCAM 1在血液透析前后的含量。结果　CRF病人在血液透析前SI CAM 1、SVCAM 1分别为 (5 0 5± 86) μg L、(1167± 12 5 ) μg L ;在血透后分别为 (3 5 0± 95 ) μg L、(884±13 1) μg L。透析前SICAM 1、SVCAM 1显著高于正常对照组 [SICAM 1(3 0 4± 78) μg L ,SVCAM 1(85 1± 114 ) μg L] ,透析后与透析前相比较有显著降低 (P <0 .0 5 )。结论　由于SICAM 1、SVCAM 1具有与炎症反应有关的免疫功能 ,因此SICAM 1和SVCAM 1血清浓度的降低对CRF病人的治疗可能是有益的     

乙型肝炎患者血清中sICAM-1水平变化的临床意义

可溶性细胞间粘附分子-1(sICAM-1)是表达内皮细胞和其他抗原递呈细胞表面上的细胞间粘附分子-1，脱落后于血液中的可溶形式，属于细胞粘附分子的免疫球蛋白超家族成员，是一种表面跨膜蛋白抗原。sICAM-1在乙型肝炎期的过度表达与机体免疫功能调节之间存在着密切关系。本文通过检测不同型期乙型肝炎患者血清中sICAM-1的浓度以探讨乙型肝炎患者sICAM-1水平变化特点及其临床意义。     

肺结核患者血中可溶性细胞间粘附分子-1水平测定的临床意义

目的 探讨可溶性细胞间粘附分子-1(sICAM-1)在肺结核免疫机制中的作用和临床意义。方法 采用酶联免疫吸附(ELISA)法测定40例未经治疗及20例治疗2个月后肺结核患者的血清sICAM-1水平,并与20例正常健康人进行对照。结果 肺结核组血清sICAM-1水平明显高于健康对照组(P<0.05),其中血行播散型肺结核(Ⅱ型)组的sICAM-1水平高于继发型肺结核(Ⅲ型)组(P<0.05)。抗结核治疗后,血清sICAM-1水平明显下降,与治疗前相比差异有显著性(P<0.05),治疗2个月后肺结核患者sICAM-1水平仍高于对照组(P<0.05)。结论 sICAM-1产生增多,可能抑制了机体的抗结核免疫,是导致肺结核病发生发展的因素之一;且sICAM-1水平越高,病情越重,治疗后随sICAM-1水平降低,病情好转。sICAM-1参与了机体的免疫机制,可作为判断肺结核严重程度及疗效判定的一个临床指标。     

类风湿关节炎中细胞间粘附分子-1的临床意义

目的 通过对类风湿关节炎(reumatoid arthritis,RA)患者血清可溶性细胞间粘附分子-1(sICAM-1)变化规律的观察,探讨sICAM-1在RA中的临床意义。方法 采用ELISA法对77例RA,25例强直性脊柱炎(ankylosing spondylitis,AS)患者血清中sICAM-1及9例RA关节液中sICAM-1水平进行检测。结果 所测静脉血清sICAM-1浓度,RA组显著高于健康人组,RA活动期组显著高于健康人组及稳定期组,RA稳定期组与健康人组差异无显著性,RA组与AS组差异无显著性;RA患者静脉血清sICAM-1浓度与治疗效果相关;RA患者静脉血清sICAM-1浓度与关节液sICAM-1浓度差异无显著性。结论 sICAM-1在RA发病中起重要作用,可用于监测RA活动及疗效。     

急性冠状动脉综合征患者血清可溶性细胞间黏附分子-1和肿瘤坏死因子-α水平及阿托伐他汀对其影响

目的：探讨急性冠脉综合征（ACS）患者可溶性细胞间粘附分子-1（sICAM-1）和肿瘤坏死因子-α（TNF—α）的变化及阿托伐他汀对sICAM-1和TNF—α的作用。方法：测定60例ACS患者、40例稳定型心绞痛（SA）患者和30例正常对照者的血清sICAM-1和TNF—α浓度。并将60例ACS患者随机分为两组：他汀组和常规组,两组均予常规治疗,他汀组加服阿托伐他汀钙片。干预4周后对他汀组及常规组再次采血测定上述指标．比较两组药物干预后血清sICAM-1、TNF—α的变化及相关性。结果：ACS组sICAM—1和TNF—α水平均明显高于SA组及对照组．差异有统计学意义。他汀组和常规组比较sICAM-1和TNF—α治疗后明显下降,差异有统计学意义。结论：阿托伐他汀具有降低ACS患者血清sICAM-1和TNF-的作用。     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

阿托伐他汀干预对急性冠状动脉综合征患者PCI术后粘附分子水平的影响

Objective To explore the impact of different dose atorvastatin on the adhesion molecules level in the acute coronary syndrome (ACS) patients who had received percutaneous coronary intervention (PCI). Methods Eighty-eight ACS patients were divided into three groups, group A (normal treatment group), group B (normal treatment plus atorvastatin 10mg per day) and group C (normal treatment plus atorvastatin 80mg per day). The patients in group B received atorvastatin 10 mg per day orally before PCI and after PCI subsequently, and the patients in group C received atorvastatin 80 mg per day orally before PCI and after PCI subsequently for three days, then the dose of atorvastatin was decrease to 10 mg per day. The concentrations of soluble intercellular adhesionmolecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) were detected before PCI and at the 3rd, 7th 14th day after PCI. Results At the 7th day, the concentrations of sICAM-1 and sVCAM-1 in group C were significantly lower than those in group B, which showed sICAM-1 (68.35±23.80) μg/L vs (131.45±29.12) μg/L and sVCAM-1 (251. 65±36.61)μg/L vs (334.87±32.98) μg/L, respectively. Compared to group A, the adhesion molecule level in group B and group C were significantly decreased (P<0.05) and had no obviously affect on blood fat level. Conclusion The treatment of atorvastatin could significantly decrease the adhesion molecules' level after PCI, which may play an important role in lowing inflammation and coronary artery restenosis after PCI.     

原发性肝癌患者血清可溶性细胞间黏附分子-1的水平及其与肝纤维化的关系

目的 研究原发性肝癌(primary hepatic carcinoma,PHC)患者血清可溶性细胞间黏附分子-1(soluble intercellular adhesion molecule-1,sICAM-1)水平及其与肝纤维化的关系.方法 选取2014年1月-2016年2月就诊并接受手术治疗的40例PHC患者作为PHC组,另选取40例肝脏良性病变患者与40例正常体检者作为良性病变组与正常组.采用酶联免疫吸附法检测3组血清sICAM-1及肝纤维化指标Ⅲ型前胶原肽(PCⅢ)、Ⅳ型胶原(Ⅳ-C)、层黏蛋白(LN)和透明质酸(HA)的水平.并比较血清sICAM-1与肝纤维化指标的相关性.结果 PHC组的血清sICAM-1、LN、PCⅢ、HA、Ⅳ-C水平明显高于良性病变组与正常组(P＜0.05),良性病变组血清sICAM-1水平高于正常组(P＜0.05).血清sICAM-1与LN、PCⅢ、HA、Ⅳ-C呈正相关性(r=0.575、0.679、0.541和0.577,P均＜0.05).结论 血清sICAM-1检测可反应PHC的发生、发展及肝细胞的损伤程度,并且与肝纤维化指标呈正相关,对PHC的早期诊断与治疗具有重要意义.     

羟乙基淀粉对下肢缺血再灌注引起的炎症反应的影响

目的观察输注羟乙基淀粉130／0．4对下肢止血带释放后引起缺血再灌注致内皮细胞功能及全身炎症反应的影响。方法40例下肢手术患者用随机数字法分为羟乙基淀粉组和对照组，各20例。采用单盲法观察。羟乙基淀粉组输注羟乙基淀粉130／0．4，对照组输注乳酸钠林格液。除上述液体外，2组均于相同静脉同时输注乳酸钠林格液。在松止血带前后不同时间点采取尿和血标本测定尿微量白蛋白／肌酐（A／C）比值和血白细胞介素_6、可溶性黏附分子水平。结果羟乙基淀粉组患者围术期晶体输入量明显低于对照组，差异有统计学意义（P〈0．05）。2组尿A／C比值在松止血带后均明显升高，至12h后恢复基础水平，其中在松止血带后15rain、4h羟乙基淀粉组明显低于对照组，差异有统计学意义（P〈0．05）。2组血IL-6水平在松止血带后各时点均明显高于基础值，羟乙基淀粉组低于对照组，差异有统计学意义（P〈0．05）。对照组血sICAM-1水平在松止血带后4h、12h明显高于基础值，而羟乙基淀粉组在没有明显改变。组间差异有统计学意义（P〈0．05）。结论使用羟乙基淀粉130／0．4可减轻下肢缺血再灌注损伤引起的毛细血管通透性增加，抑制过度的炎症反应和内皮细胞功能障碍。     

雷达兵细胞粘附分子的变化及其红细胞免疫功能所受影响

目的研究雷达兵细胞粘附分子的变化及对红细胞免疫功能的影响。方法可溶性血管细胞粘附细胞分子1(sVCAM-1)、IL-6测定取外周静脉血,采用双抗体夹心ELISA法检测。采用PCR-HindⅢ酶切技术和酵母菌多糖花环试验对雷达兵进行红细胞CR1基因组密度多态性分布和红细胞免疫功能检测。结果雷达兵sVCAN-1(1576．8±42．76)ng／ml较对照组(714．85±276．54)ng／ml明显增高,雷达兵IL-6 (129．58±74．58)pg／／ml较对照组(54．61±32．41)pg／ml明显增高,两者差异显著;雷达兵红细胞CR1基因组密度多态性分布HH型占58．06％,HL型占32．26％,LL型占9．68％,雷达兵红细胞免疫功能低下。结论由于雷达兵在特殊环境下工作,sVCAM-1、IL-6细胞因子发生明显变化,其红细胞膜相CR1基因组密度多态性分布较对照组也有明显差异,这可能是红细胞的免疫功能降低的一个重要原因。     

急性白血病患者中ICAM-1和VCAM-1的表达及意义

目的 探讨细胞间黏附分子1(ICAM-1)和血管细胞间黏附分子1(VCAM-1)在急性白血病(AL)中的表达及临床意义.方法 39例初诊AL患者,其中27例经治疗后达完全缓解(CR).采用逆转录-PCR法检测AL骨髓单个核细胞ICAM-1和VCAM-1的mRNA表达水平.对照组12例均为骨髓像正常的门诊患者.结果 ICAM-1和VCAM-1水平在初诊AL者明显高于CR组及对照组(P＜0.01),且CR组和对照组之间无显著差异(P＞0.05);高白细胞(WBC＞100×109/L)组和死亡组的ICAM-1和VCAM-1水平明显增高(P＜0.05).髓外浸润组仅ICAM-1高于非髓外浸润组(P＜0.01);非淋巴细胞AL(ANLL)具有良好核型者ICAM-1水平低于其他患者(P＜0.05).结论 AL表达ICAM-1和VCAM-1明显增高,其检测对疗效及预后判断有重要意义.     

丹参注射液对不稳定型心绞痛患者血清可溶性细胞间黏附分子 1的影响

目的： 探讨不稳定型心绞痛(UAP)患者血清中可溶性细胞间黏附分子 1(sICAM 1)和C 反应蛋白(CRP)的水平与正常人的差异，及其在丹参注射液治疗前后的变化。方法：将64例UAP患者随机分为对照组1(常规治疗组)31例及治疗组(丹参注射液治疗组)33例，对照组1采用常规治疗即吸氧，镇静，阿司匹林100 mg，qd；美托洛尔12.5～25 mg，每天2或3次。治疗组在常规治疗基础上，给予丹参注射液30 mL加5%葡萄糖注射液250 mL，静脉滴注，qd。两组疗程均为14 d。通过ELISA法检测治疗前后血清sICAM 1和CRP水平的变化，并与对照组2(正常对照组)22例对比分析。观察两组疗效。结果：UAP患者血清sICAM 1和CRP水平较对照组2明显升高(均为P＜0.01)，对照组1及治疗组治疗后sICAM 1及CRP水平较治疗前明显降低(均为P＜0.01)，且治疗组下降幅度显著较对照组1大(P＜0.05)。治疗组较对照组1临床疗效更显著(P＜0.05)，但心电图疗效差异无显著性(P＞0.05)。结论：CRP、sICAM 1可能参与了冠心病(CHD)的发病过程，血清sICAM 1的检测有助于临床病情分析，丹参注射液能显著降低UAP患者血清sICAM 1和CRP水平，与常规西药联合治疗冠心病疗效更好，从而降低冠状动脉事件的发生率。     

甲状腺疾病患者血清可溶性细胞间黏附分子-1测定的临床意义

Objective To explore the contents and clinical significance of soluble intracellular adhesion molecule-1 ( sICAM-1 ) in patients with single goitre,Graves'and Hashimoto disease. Methods The contents of sICAM-1 in 100 cases of simple goiter group, Graves disease (GD) group 250 cases, Hashimot group 50 cases and 100 normal control were examined by sICAM-1 Radioimmunoassay(RIA) method,and the results were analyzed. Results There were no significant difference of sICAM-1 contents between ( 170.43 ± 34. 23 ) μg/L in normal control group and ( 182.48 ± 40.05) μg/L in simple goiter group( t = 1. 104, P ＞ 0. 05 ); The contents of slCAM-1 in GD group and HT group [( 279.93 ± 86.69) μg/L、 (250.36 ± 81.56) μg/L] were higher than the control group( t = 2.310,2. 210, all P ＜0. 05) ;The sICAM-1 contents in 3 species.methods after treatment [( 178.95 ±59.78) μg/L, ( 185.65 ±53.25)μg/L, (259.41 ± 71.46) μg/L)] were significantly lower than before treatment [(316.53 ± 66.13) μg/L, (277.79±64.30)μg/L,(285.71 ±72.14)μg/L](t=2.312,2.278,2.328,all P ＜0.05);After the Graves'patients were treated and their thyroid function were normal,their serum sICAM-1 levels( 251.92 ± 77.75 )μg/L were lower than that( 329.34 ± 90.47 ) μg/L in relapse Graves'group( t= 2.412 ,P ＜ 0. 05). Conclusion sICAM-1 RIA can be used as a parameter in diagnosing autoimmune thyroid diseases and in evaluating effects of therapy,stopping medicine or the relapse of Graves' disease.     

厄贝沙坦对实验性糖尿病大鼠肾脏的保护作用

目的 探讨厄贝沙坦对实验性糖尿病大鼠肾脏的保护作用及其可能机制.方法 Wismr健康大鼠24只,随机分为对照组、模型组、药物组,每组8只.链脲佐菌素诱导糖尿病大鼠模型,8周后抽血测血糖(BG)、糖化血红蛋白(HbAlc)、尿索氮(BUN)和肌酐(SCr),计算尿白蛋白分泌率(UAER).用免疫组化检测大鼠肾脏细胞间黏附分子1(ICAM-1),Western blot检测血管细胞黏附分子1(VCAM-1)蛋白表达水平.结果 模型组与药物组的BG、HbAlc、BUN、SCr都高于对照组(P＜0.05).模型组UAER高于对照组.而药物组则低于模型组(P＜0.05).药物组ICAM-l与VCAM-l蛋白表达量低于模型组(P＜0.05).结论 厄贝沙坦对实验性糖尿病大鼠的肾脏有保护作用,可能与抑制ICAM-l与VCAM-l在肾脏的表达有关.     

骨折患者术后不愈合血清炎症因子变化的临床研究

目的了解骨折术后不愈合患者血清炎症因子变化与临床的关系。方法32例骨折术后不愈合患者（不愈合组）血清肿瘤坏死因子-α（TNF-α）、可溶性血管细胞间黏附分子-1（sVCAM-1）和白细胞介素-18（IL-1B）水平进行检测,并与32例健康体检者（对照组）和36例骨折术后Ⅰ期愈合患者（Ⅰ期愈合组）比较。结果不愈合组血清IL-1β、TNF-α和sVCAM-1水平高于对照组和Ⅰ期愈合组患者,差异有统计学意义（P〈0．05）。结论骨折术后不愈合患者内皮功能受损,巨噬细胞被活化,引起多种细胞因子的释放,从而影响骨折术后愈合。     

支气管哮喘患儿血清可溶性细胞间黏附分子-1的测定

目的 :探讨可溶性细胞间黏附分子 -1(sICAM -1)与哮喘的关系及激素对其的影响。方法 :采用放射免疫法测定30例哮喘患儿 (哮喘组 ) ,30例健康小学生 (正常对照组 )的血清sICAM -1。结果 :(1)哮喘组急性发作期及缓解期血清sICAM -1水平均较正常对照组高 (均P<0.01)。(2)哮喘患儿在缓解期血清sICAM -1水平较急性发作期明显下降 (P<0.01) ;9例服强的松的哮喘患者 ,其血清ICAM -1水平在服药期间低于停用激素1周后 ,差异有统计学意义 (P<0.05)。结论 :(1)黏附分子可能参与了哮喘的发生与发作 ,其水平的高低可能与哮喘的活动度有关。 (2)激素可能通过抑制血清ICAM -1的升高而起到控制及预防哮喘发作的作用